Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.61 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469844 | 0.87 | FLT3 (0.42) | FLT3KITNTRK3ST14F7 | |
| SCHEMBL17469875 | 0.82 | FLT3 (0.41) | FLT3KITNTRK3ST14EGFR | |
| SCHEMBL17469734 | 0.81 | KIT (0.64) | FLT3KITNTRK3ST14F2 | |
| SCHEMBL17469624 | 0.76 | KIT (0.44) | FLT3KITNTRK3ST14F7 | |
| SCHEMBL17469649 | 0.76 | KIT (1.00) | FLT3KITNTRK3ST14F2 | |
| SCHEMBL21153043 | 0.72 | TOP2A (0.41) | FLT3ALDH1A1MAPK1 | |
| SCHEMBL17469778 | 0.72 | KIT (0.70) | FLT3KITNTRK3ST14MAPK1 | |
| SCHEMBL17469639 | 0.72 | KIT (0.67) | FLT3KITNTRK3ST14MAPK1 | |
| SCHEMBL17469621 | 0.70 | F7 (0.43) | ST14F7F3F2ALDH1A1 | |
| SCHEMBL17469655 | 0.69 | KIT (0.79) | FLT3KITNTRK3ST14F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | FLT3 2354/4885KIT 2616/4885NTRK3 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.